Business & FinanceTop StoryTop StoryLatest News
Bharat Biotech's Nucelion Partners with VeGen Bio for Advanced Cancer Treatment
Sentiment: NeutralHigh Priority
What Happened?
Bharat Biotech's subsidiary Nucelion Therapeutics has teamed up with VeGen Bio to manufacture CAR-T therapy VL-2511 for multiple myeloma. The partnership aims for clinical trials in India by 2028.
Key points
- Nucelion will provide technology transfer and manufacturing services for VL-2511.
- The therapy targets multiple myeloma, a type of blood cancer.
- Clinical trials are planned in India, aiming for commercialization by 2028.
- Nucelion's facility in Hyderabad will be used for production processes.
- The partnership is part of Bharat Biotech's strategy to expand into advanced biological treatments.
Key insights
- The collaboration may lead to reduced manufacturing costs for CAR-T therapies.
- Improved efficiency in production could make advanced treatments more affordable.
- This partnership highlights the growing interest in cell and gene therapies in India.
Why it matters
This partnership could enhance access to advanced cancer treatments in India.
Tags
Entities
Bharat Biotech· CompanyNucelion Therapeutics· CompanyVeGen Bio· Companymultiple myeloma· DiseaseHyderabad· CityIndia· Country
Source
Business Standard
